{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:55:40Z","timestamp":1791208540858,"version":"4.1.0"},"reference-count":22,"publisher":"EDP Sciences","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Sci (Paris)"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1051\/medsci\/200925121046","type":"journal-article","created":{"date-parts":[[2011,3,3]],"date-time":"2011-03-03T10:02:37Z","timestamp":1299146557000},"page":"1046-1052","source":"Crossref","is-referenced-by-count":18,"title":["Les immunoconjugu\u00e9s, anticorps \u00ab\u00a0arm\u00e9s\u00a0\u00bb pour combattre le cancer"],"prefix":"10.1051","volume":"25","author":[{"given":"Jean-Fran\u00e7ois","family":"Haeuw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Caussanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"250","published-online":{"date-parts":[[2009,12,15]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics.Nat Rev Drug Discovery2006; 5 : 147\u201359.","DOI":"10.1038\/nrd1957"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Wu AM, Senter PD. Arming antibodies : prospects and challenges for immunoconjugates.Nat Biotech2005; 23 : 1137\u201346.","DOI":"10.1038\/nbt1141"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Tolcher AW, Sugarman S, Gelmon KA,et al.Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.J Clin Oncol1999; 17 : 478\u201384.","DOI":"10.1200\/JCO.1999.17.2.478"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer.Curr Opin Pharm2005; 5 : 543\u20139.","DOI":"10.1016\/j.coph.2005.04.017"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Chari RVJ. Targeted cancer therapy : conferring specificity to cytotoxic drugs.Acc Chem Res2008; 41 : 98\u2013107.","DOI":"10.1021\/ar700108g"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Amadori S, Stasi R. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukaemia.Curr Opin Hematol2008; 15 : 95\u2013100.","DOI":"10.1097\/MOH.0b013e3282f3de84"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Stasi R. Gemtuzumab ozogamicin : an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.Expert Opin Biol Ther2008; 8 : 527\u201340.","DOI":"10.1517\/14712598.8.4.527"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Walters RB, Gooley TA, Van Der Velden VH,et al.CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukaemia treated with gemtuzumab ozogamicin monotherapy.Blood2007; 109 : 4168\u201370.","DOI":"10.1182\/blood-2006-09-047399"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Di Joseph JF, Armellino DC, Boghaert ER,et al.Antibody-targeted chemotherapy with CMC-544 : a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.Blood2004; 103 : 1807\u201314.","DOI":"10.1182\/blood-2003-07-2466"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Chan SY, Gordon AN, Coleman RE,et al.A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hctM01-calicheamicin) in patient with platinum-sensitive recurrent epithelial ovarian carcinoma.Cancer Immunol Immunother2003; 52 : 243\u20138.","DOI":"10.1007\/s00262-002-0343-x"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Lewis Phillips GD, Li G, Dugger DL,et al.Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjuguate.Cancer Res2008; 68 : 9280\u201390.","DOI":"10.1158\/0008-5472.CAN-08-1776"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Erickson HK, Park PU, Widdison WC,et al.Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.Cancer Res2006; 66 : 4426\u201333","DOI":"10.1158\/0008-5472.CAN-05-4489"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Sanderson RJ, Hering MA, James SF,et al. In vivodrug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.Clin Cancer Res2005; 11 : 843\u201352.","DOI":"10.1158\/1078-0432.843.11.2"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Tse KF, Jeffers M, Pollack VA,et al.CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.Clin Cancer Res2006; 12 : 1373\u201382.","DOI":"10.1158\/1078-0432.CCR-05-2018"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates.Cancer Lett2007; 255 : 232\u201340.","DOI":"10.1016\/j.canlet.2007.04.010"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Polson AG, Calemine-Fenaux J, Chan P,et al.Antibody-drug conjugates for the treatment of non-Hodgkin\u2019s lymphoma : target and linker-drug selection.Cancer Res2009; 69 : 2358\u201364.","DOI":"10.1158\/0008-5472.CAN-08-2250"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Law CH, Cerveny CG, Gordon KA,et al.Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.Clin Cancer Res2004; 10 : 7842\u201351.","DOI":"10.1158\/1078-0432.CCR-04-1028"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Ingle GS, Chan P, Elliott JM,et al.High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of antiCD19-drug conjugate.Br J Haematol2007; 140 : 46\u201358.","DOI":"10.1111\/j.1365-2141.2007.06883.x"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Kovtun YV, Audette CA, Ye Y,et al.Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.Cancer Res2006; 66 : 3214\u201321.","DOI":"10.1158\/0008-5472.CAN-05-3973"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Doronina SO, Toki BE, Torgov MY,et al.Development of potent monoclonal antibody auristatin conjugates for cancer therapy.Nat Biotechnol2003; 21 : 778\u201384.","DOI":"10.1038\/nbt832"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Doronina SO, Mendelsohn BA, Bovee TD,et al.Enhanced activity of monomethylauristatin F through monoclonal antibody delivery : effect of linker technology on efficacy and toxicity.Bioconjug Chem2006; 17 : 114\u201324.","DOI":"10.1021\/bc0502917"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Ojima I. Guided molecular missiles for tumor-targeting chemotherapy : case studies using the second generation taxoids as warheads.Acc Chem Res2008; 41 : 108\u201319.","DOI":"10.1021\/ar700093f"}],"container-title":["m\u00e9decine\/sciences"],"original-title":[],"link":[{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/200925121046\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T13:30:58Z","timestamp":1685971858000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/200925121046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":22,"journal-issue":{"issue":"12"},"alternative-id":["medsci20092512p1046"],"URL":"https:\/\/doi.org\/10.1051\/medsci\/200925121046","relation":{},"ISSN":["0767-0974","1958-5381"],"issn-type":[{"value":"0767-0974","type":"print"},{"value":"1958-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}